文献速递复苏、休克与脓毒症消化、代谢与肾脏急症

膜渗透性肌球蛋白轻链激酶抑制剂加重小鼠多微生物脓毒症生存

Membrane Permeant Inhibitor of Myosin Light Chain Kinase Worsens Survival in Murine Polymicrobial Sepsis.
PubMed 文献 · Shock · 2021-01-01
一句话结论在盲肠结扎穿刺脓毒症小鼠中,药理学抑制MLCK(PIK)反而使7天生存率从62%降至24%,提示靶向肠道屏障需谨慎。

本研究在C57BL/6小鼠行盲肠结扎穿刺诱导脓毒症后随机给予MLCK膜渗透性抑制剂PIK或溶媒。意外发现PIK显著恶化7天生存(24% vs 62%)。PIK增加FD-4(28Å)经漏路径的肠道通透性,而未改变孔路径或无限制路径;空肠紧密连接磷酸化MLC增加,但occludin、ZO-1、JAM-A无变化。PIK对系统或腹腔细菌负荷、细胞因子、脾或Peyer集合淋巴结免疫细胞及肠道完整性无显著影响。结果提示药理学抑制MLCK增加死亡率并与漏路径通透性恶化相关,靶向肠道屏障治疗脓毒症需谨慎。

要点

  • 在CLP脓毒症小鼠中,PIK组7天生存率24%,溶媒组62%,PIK显著恶化生存。
  • PIK增加肠道漏路径通透性,表现为血中FD-4(28Å)水平高于溶媒组。
  • PIK未改变孔路径或无限制路径通透性,也未改变系统或腹腔细菌负荷、细胞因子及肠道完整性。
  • PIK组空肠紧密连接磷酸化MLC增加,occludin、ZO-1、JAM-A无变化。
  • 药理学抑制MLCK在脓毒症中可能有害,靶向肠道屏障治疗需谨慎。

适用人群与场景

  • C57BL/6小鼠行盲肠结扎穿刺诱导的多微生物脓毒症模型。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:动物实验(小鼠),样本量原文未提及,单中心。
  • 人群:C57BL/6小鼠行盲肠结扎穿刺诱导脓毒症。
  • 干预与对照:随机接受PIK或溶媒。
  • 主要终点:7天生存率,PIK组24% vs 溶媒组62%,PIK显著恶化生存(原文未提供P值)。
  • 次要终点:PIK增加漏路径通透性(血FD-4水平高于溶媒组),孔路径和无限制路径无差异;磷酸化MLC增加,occludin、ZO-1、JAM-A无变化;系统或腹腔细菌负荷、细胞因子、脾或Peyer集合淋巴结免疫细胞及肠道完整性无显著差异。

证据类型、等级与局限

  • 证据类型:动物实验(小鼠模型)。
  • 证据等级或推荐强度:原文未提及。
  • 局限:动物模型,样本量原文未提及,单中心,结果需临床验证。

对床旁实践的改变

  • 在脓毒症中不应基于遗传性MLCK缺失的有益结果而假设药理学抑制MLCK同样获益;本研究显示PIK恶化生存,提示靶向肠道屏障治疗需谨慎。
  • 适用人群:仅限本小鼠脓毒症模型,不能直接外推至临床患者。
  • 常见陷阱:将遗传学干预结果直接转化为药理学策略可能有害。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

Sepsis-induced intestinal hyperpermeability is mediated by disruption of the epithelial tight junction, which is closely associated with the peri-junctional actin-myosin ring. Genetic deletion of myosin light chain kinase (MLCK) reverses intestinal hyperpermeability and improves survival in a murine model of intra-abdominal sepsis. In an attempt to determine whether these findings could be translated using a more clinically relevant strategy, this study aimed to determine if pharmacologic inhibition of MLCK using the membrane permeant inhibitor of MLCK (PIK) improved gut barrier function and survival following sepsis. C57BL/6 mice underwent cecal ligation and puncture to induce sepsis and were then randomized to receive either PIK or vehicle. Unexpectedly, PIK significantly worsened 7-day survival following sepsis (24% vs. 62%). The three pathways of intestinal permeability were then interrogated by orally gavaging septic mice with creatinine (6Å), FD-4 (28Å), and rhodamine70 (120Å) and assaying their appearance in the bloodstream. PIK led to increased permeability in the leak pathway with higher levels of FD-4 in the bloodstream compared to septic mice given vehicle. In contrast, no differences were detected in the pore or unrestricted pathways of permeability. Examination of jejunal tight junctions for potential mechanisms underlying increased leak permeability revealed that mice that received PIK had increased phosphorylated MLC without alterations in occludin, ZO-1, or JAM-A. PIK administration was not associated with significant differences in systemic or peritoneal bacterial burden, cytokines, splenic or Peyer's Patches immune cells or intestinal integrity. These results demonstrate that pharmacologic inhibition of MLCK unexpectedly increases mortality, associated with worsened intestinal permeability through the leak pathway, and suggest caution is required in targeting the gut barrier as a potential therapy in sepsis.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Sun Y, Oami T, Liang Z, et al. Membrane Permeant Inhibitor of Myosin Light Chain Kinase Worsens Survival in Murine Polymicrobial Sepsis. Shock. 2021. PMID: 33606476. doi:10.1097/SHK.0000000000001759

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。